Aardvark Therapeutics (AARD) vs Equillium (EQ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Equillium (EQ) has outperformed Aardvark Therapeutics (AARD) over the past year, gaining 17.2% versus a loss of 69.6%. Aardvark Therapeutics is the larger company by market cap ($97.4 million vs $95.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | EQ |
|---|---|---|
| Share price | $4.45 | $1.50 |
| Market cap | $97.39M | $95.11M |
| 1-day change | -6.51% | +6.38% |
| YTD return | -66.10% | -3.23% |
| 1-year return | -69.58% | +17.19% |
| 5-year return | — | -74.40% |
| EPS (TTM) | $-3.21 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.60 | $3.54 |
| 52-week low | $3.35 | $0.76 |
| Distance from 52-week high | -73.19% | -57.63% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +149.66% | +470.67% |
| Average volume | 146.39K | 564.39K |
| Shares outstanding | 21.88M | 63.41M |
| Employees | 28 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed AARD by 86.8 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
AARD vs EQ FAQ
Which is bigger, Aardvark Therapeutics or Equillium?
Aardvark Therapeutics (AARD) is larger, with a market capitalization of $97.39M compared with $95.11M for Equillium (EQ).
Which stock has performed better over the past year, AARD or EQ?
EQ returned +17.19% over the past 12 months, compared with -69.58% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Equillium in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.